nach oben

Neurological Sciences

Erschienen in:

21.03.2022 | Review Article

Real-time quaking-induced conversion assay is accurate for Lewy body diseases: a meta-analysis

verfasst von: Yashan Wang, Jiayi Hu, Xiaofei Chen, Song Wang, Chenyang Zhang, Junjun Hu, Dingjie Guo, Xin Liu

Erschienen in: Neurological Sciences | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

Real-time quaking-induced conversion (RT-QuIC) is a novel in vitro acellular seed amplification analysis and has been widely used to detect prion diseases. Due to the similar mechanism of abnormal aggregation of α-synuclein, RT-QuIC has great potential for diagnosing Lewy body diseases. This meta-analysis was performed to evaluate the diagnostic accuracy of RT-QuIC for Lewy body diseases.

Methods

This study followed the PRISMA statement. We searched six databases for relevant studies published until February 20, 2022. Meta-analysis was conducted using RevMan 5.3, Stata 17.0, and Meta-Disc 1.4. Subgroup analyses were performed to explore sources of heterogeneity.

Results

A total of 16 studies were included in this study. The pooled sensitivity and specificity were 0.91 (95%CI: 0.85–0.94) and 0.95 (95%CI: 0.90–0.97), respectively. The pooled positive and negative likelihood ratios were 17.16 (95% CI: 9.16–32.14) and 0.10 (95% CI: 0.06–0.17), respectively. The pooled diagnostic odds rate and area under the summary receiver operating characteristic curve were 171.16 (95% CI: 66.64–439.62) and 0.97 (95% CI: 0.96–0.99), respectively.

Conclusions

This study was the first meta-analysis on RT-QuIC for Lewy body diseases. RT-QuIC is a reliable and accurate method to diagnose Lewy body diseases.

Nur mit Berechtigung zugänglich

PezzoliS, Cagnin A, Bandmann O, Venneri A (2017) Structural and Functional Neuroimaging of Visual Hallucinations in Lewy body disease: a systematic literature review. Brain Sci 7(7)

Goldstein DS, Holmes C, Kopin IJ, Sharabi Y (2011) Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. J Clin Investig 121(8):3320–3330CrossRef

Hama Y, Katsu M, Takigawa I, Yabe I, Matsushima M, Takahashi I, Katayama T, Utsumi J, Sasaki H (2017) Genomic copy number variation analysis in multiple system atrophy. Mol Brain 10(1):54CrossRef

Rongve A, Witoelar A, Ruiz A, Athanasiu L, Abdelnour C, Clarimon J, Heilmann-Heimbach S, Hernández I, Moreno-Grau S, de Rojas I, Morenas-Rodríguez E, Fladby T, Sando SB, Bråthen G, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Londos E, Almdahl IS, Pålhaugen L, Eriksen JA, Djurovic S, Stordal E, Saltvedt I, Ulstein ID, Bettella F, Desikan RS, Idland A-V, Toft M, Pihlstrøm L, Snaedal J, Tárraga L, Boada M, Lleó A, Stefánsson H, Stefánsson K, Ramírez A, Aarsland D, Andreassen OA (2019) GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Sci Rep 9(1):7013CrossRef

Nido GS, Dick F, Toker L, Petersen K, Alves G, Tysnes O-B, Jonassen I, Haugarvoll K, Tzoulis C (2020) Common gene expression signatures in Parkinson’s disease are driven by changes in cell composition. Acta Neuropathol Commun 8(1):55CrossRef

Gratwicke J, Zrinzo L, Kahan J, Peters A, Beigi M, Akram H, Hyam J, Oswal A, Day B, Mancini L, Thornton J, Yousry T, Limousin P, Hariz M, Jahanshahi M, Foltynie T (2018) Bilateral deep brain stimulation of the nucleus basalis of Meynert for Parkinson disease dementia. JAMA Neurol 75(2):169CrossRef

Rossi M, Candelise N, Baiardi S, Capellari S, Giannini G, Orrù CD, Antelmi E, Mammana A, Hughson AG, Calandra-Buonaura G, Ladogana A, Plazzi G, Cortelli P, Caughey B, Parchi P (2020) Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140(1):49–62CrossRef

De Luca CMG, Elia AE, Portaleone SM, Cazzaniga FA, Rossi M, Bistaffa E, De Cecco E, Narkiewicz J, Salzano G, Carletta O, Romito L, Devigili G, Soliveri P, Tiraboschi P, Legname G, Tagliavini F, Eleopra R, Giaccone G, Moda F (2019) Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy. Transl Neurodegener 8(1)

Bongianni M, Ladogana A, Capaldi S, Klotz S, Baiardi S, Cagnin A, Perra D, Fiorini M, Poleggi A, Legname G, Cattaruzza T, Janes F, Tabaton M, Ghetti B, Monaco S, Kovacs GG, Parchi P, Pocchiari M, Zanusso G (2019) alpha-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann Clin Transl Neurol 6(10):2120–2126CrossRef

10.

Groveman BR, Orrù CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B, Campbell KJ, Safar J, Galasko D, Caughey B (2018) Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. Acta Neuropathol Commun 6(1):7CrossRef

11.

Mammana A, Baiardi S, Rossi M, Franceschini A, Donadio V, Capellari S, Caughey B, Parchi P (2020) Detection of prions in skin punch biopsies of Creutzfeldt-Jakob disease patients. Ann Clin Transl Neurol 7(4):559–564CrossRef

12.

Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ, Singh N, Tatsuoka C, Appleby B, Zhu X, Xu R, Haroutunian V, Zou WQ, Ma J, Chen SG (2021) Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9(1):62CrossRef

13.

Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, Joachim C, Esiri M, Evetts SG, Rolinski M, Baig F, Ruffmann C, Wade-Martins R, Hu MT, Parkkinen L, Green AJ (2016) Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 3(10):812–818CrossRef

14.

Manne S, Kondru N, Hepker M, Jin H, Anantharam V, Lewis M, Huang X, Kanthasamy A, Kanthasamy AG (2019) Ultrasensitive detection of aggregated α-synuclein in glial cells, human cerebrospinal fluid, and brain tissue using the RT-QuIC assay: new high-throughput neuroimmune biomarker assay for Parkinsonian disorders. J Neuroimmune Pharmacol 14(3):423–435CrossRef

15.

Mammana A, Baiardi S, Quadalti C, Rossi M, Donadio V, Capellari S, Liguori R, Parchi P (2021) RT-QuIC detection of pathological α-synuclein in skin punches of patients with Lewy body disease. Mov Disord 36(9):2173–2177CrossRef

16.

Garrido A, Fairfoul G, Tolosa ES, Martí MJ, Green A (2019) α-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson’s disease. Ann Clin Transl Neurol 6(6):1024–1032CrossRef

17.

van Rumund A, Green AJE, Fairfoul G, Esselink RAJ, Bloem BR, Verbeek MM (2019) α-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. Ann Neurol 85(5):777–781CrossRef

18.

Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM, Holguin B, Hughson AG, LaFontant DE, Caspell-Garcia C, Coffey CS, Mollon J, Hutten SJ, Merchant K, Heym RG, Soto C, Caughey B, Kang UJ (2021) High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease. Acta Neuropathol Commun 9(1):179CrossRef

19.

Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A, Trenkwalder C, Sixel-Doring F, Foubert-Samier A, Le Traon AP, Plazzi G, Biscarini F, Montplaisir J, Gagnon J-F, Postuma RB, Antelmi E, Meissner WG, Mollenhauer B, Ben-Shlomo Y, Hu MT, Parkkinen L (2021) Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain J Neurol

20.

Perra D, Bongianni M, Novi G, Janes F, Bessi V, Capaldi S, Sacchetto L, Tagliapietra M, Schenone G, Morbelli S, Fiorini M, Cattaruzza T, Mazzon G, Orrù CD, Catalan M, Polverino P, Bernardini A, Pellitteri G, Valente M, Bertolotti C, Nacmias B, Maggiore G, Cavallaro T, Manganotti P, Gigli G, Monaco S, Nobili F, Zanusso G (2021) Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. Brain Commun 3(2):fcab045CrossRef

21.

Orru CD, Ma TC, Hughson AG, Groveman BR, Srivastava A, Galasko D, Angers R, Downey P, Crawford K, Hutten SJ, Kang UJ, Caughey B (2021) A rapid alpha-synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracy. Ann Clin Transl Neurol 8(2):374–384CrossRef

22.

Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I, Sanchez-Valle R, Gaig C, Santamaria J, Tolosa E, Riha RL, Green AJE (2021) Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol 20(3):203–212CrossRef

23.

Donadio V, Wang Z, Incensi A, Rizzo G, Fileccia E, Vacchiano V, Capellari S, Magnani M, Scaglione C, Stanzani Maserati M, Avoni P, Liguori R, Zou W (2021) In vivo diagnosis of synucleinopathies: a comparative study of skin biopsy and RT-QuIC. Neurology 96(20):e2513–e25245CrossRef

24.

Brockmann K, Quadalti C, Lerche S, Rossi M, Wurster I, Baiardi S, Roeben B, Mammana A, Zimmermann M, Hauser AK, Deuschle C, Schulte C, Waniek K, Lachmann I, Sjödin S, Brinkmalm A, Blennow K, Zetterberg H, Gasser T, Parchi P (2021) Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9(1):175CrossRef

25.

Paciotti S, Bellomo G, Gatticchi L, Parnetti L (2018) Are we ready for detecting α-synuclein prone to aggregation in patients? The case of “protein-misfolding cyclic amplification” and “real-time quaking-induced conversion” as diagnostic tools. Front Neurol 9:415CrossRef

26.

Garrido A, Fairfoul G, Tolosa ES, Jose Marti M, Green A, Compta Y, Valldeoriola F, Munoz E, Fernandez M, Alvarez R, Vilas D, Ispierto L, De Fabregues O, Hernandez-Vara J, Puente V, Calopa M, Jauma S, Campdelacreu J, Bayes A, Avila A, Caballol N, Aguilar M, Casquero P, Barcelona LSG (2019) Alpha-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson’s disease. Ann Clin Transl Neurol 6(6):1024–1032CrossRef

27.

Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, Incensi A, Kuzkina A, Orrú CD, Tatsuoka C, Liguori R, Gunzler SA, Caughey B, Jimenez-Capdeville ME, Zhu X, Doppler K, Cui L, Chen SG, Ma J, Zou WQ (2021) Skin α-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol 78(1):30–40CrossRef

28.

Manne S, Kondru N, Jin H, Anantharam V, Huang X, Kanthasamy A, Kanthasamy AG (2020) α-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson’s disease patients. Mov Disord 35(2):268–278CrossRef

Titel: Real-time quaking-induced conversion assay is accurate for Lewy body diseases: a meta-analysis
verfasst von: Yashan Wang
Jiayi Hu
Xiaofei Chen
Song Wang
Chenyang Zhang
Junjun Hu
Dingjie Guo
Xin Liu
Publikationsdatum: 21.03.2022
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 7/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-06014-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2022

Relationship between dysphagia severity and head and neck proprioception in patients with neurological disorders

Neurophysiological challenges in myasthenia gravis associated with MuSK antibodies: a case report

Posterior reversible encephalopathy syndrome: an atypical neurological manifestation of SARS-CoV-2 infection

A new Chinese family with HTRA1 mutation associated with CARASIL

A splice altering variant in NDRG1 gene causes Charcot-Marie-Tooth disease, type 4D